By Amanda Psyrri The findings of KEYNOTE-055 are summarized and compared to other immunotherapy studies in recurrent/metastatic head and neck squamous cell carcinoma. Related Article: <a style= "font-size: 8pt;" href= "http://ascopubs.org/doi/abs/10.1200%2FJCO.2016.70.1524">Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study</a>

By Amanda Psyrri The findings of KEYNOTE-055 are summarized and compared to other immunotherapy studies in recurrent/metastatic head and neck squamous cell carcinoma. Related Article: Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

By Amanda Psyrri The findings of KEYNOTE-055 are summarized and compared to other immunotherapy studies in recurrent/metastatic head and neck squamous cell carcinoma. Related Article: <a href="http://ascopubs.org/doi/abs/10.1200%2FJCO.2016.70.1524" rel="noopener noreferrer">Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study</a>

Pembrolizumab is Safe and Active in Platinum- and Cetuximab-Refractory Head and Neck Squamous Cell Carcinoma

The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin and Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO's esteemed Journal of Clinical Oncology. Through scholarly discourse and examination, this podcast is your resource for navigating oncological advancements and how they impact clinical practice.

The JCO Podcast also features in depth summaries and interviews hosted by the year's fellows in the series, JCO Article Insights.

Medicine

Health & Fitness

The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin and Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO's esteemed Journal of Clinical Oncology. Through scholarly discourse and examination, this podcast is your resource for navigating oncological advancements and how they impact clinical practice. The JCO Podcast also features in depth summaries and interviews hosted by the year's fellows in the series, JCO Article Insights.

Share Pembrolizumab is Safe and Active in Platinum- and Cetuximab-Refractory Head and Neck Squamous Cell Carcinoma

Sign up to save your podcasts

Pembrolizumab is Safe and Active in Platinum- and Cetuximab-Refractory Head and Neck Squamous Cell Carcinoma

Pembrolizumab is Safe and Active in Platinum- and Cetuximab-Refractory Head and Neck Squamous Cell Carcinoma

More shows like Journal of Clinical Oncology (JCO) Podcast

NPR News Now

JAMA Editors' Summary

NEJM This Week

JAMA Clinical Reviews

ASCO Daily News

The Daily

ASCO Guidelines

ASCO Education

Annals On Call Podcast

JAMA Medical News

Harrison's PodClass: Internal Medicine Cases and Board Prep

Run the List

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions

The Headlines